Serotonin transporters: Implications for antidepressant drug development

AAPS Journal

Volumn 7, Issue 2, 2005, Pages

  White, Kellie J ^a   Walline, Crystal C ^a   Barker, Eric L ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Antidepressant; Depression; Reuptake; Serotonin transporter; SSRIs

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; BRIMONIDINE; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; IPRONIAZID; LITHIUM; MAPROTILINE; MAZINDOL; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PINDOLOL; REBOXETINE; SEROTONIN TRANSPORTER; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ARTICLE; ATTENTION DEFICIT DISORDER; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; HUMAN; HYPERTENSIVE CRISIS; LIVER TOXICITY; LONG TERM CARE; MOLECULAR INTERACTION; MONOAMINERGIC SYSTEM; NONHUMAN; NORADRENERGIC SYSTEM; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 30544439942     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070242     Document Type: Article

References (89)

1. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996;29:2-11.
2. Nutt DJ. The reuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol. 2002,17:S1-12.
3. Rush A, Ryan N. Current and emerging therapeutics for depression. In: Davis K, Charney D, Coyle J, Nemeroff C. eds. Neuropsychopharmacology: The Fifth Generation of Progress. New York: Raven Press, 2002:1081-1095
4. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997,283:1305-1322.
5. Ban TA. Pharmacotherapy of depression: a historical analysis. J Neural Transm. 2001;108:707-716.
6. Richelson E. The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacol Bull. 2001,36:133-150.
7. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997;6:10-18.
8. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993;306:683-687.
9. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry. 2000;61:26-32.
10. Gutierrez MA. Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin Ther. 2003;25:2138-2154.
11. Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry. 2003;64:13-17.
12. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry. 2004;65:5-10.
13. Barker EL, Perlman MA, Adkins EM, et al. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J Biol Chem. 1998-273:19459-19468.
14. Ravna AW, Sylte I, Dahl SG. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters. J Pharmacol Exp Ther. 2003;307:34-41.
15. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA. 1992;89:7782-7785.
16. Barker EL, Moore KR, Rakhshan F, Blakely RD. Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci. 1999;19:4705-4717.
17. Paczkowski FA, Bryan-Lluka LJ. Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology. Brain Res Mol Brain Res. 2001;97:32-42.
18. Roubert C, Cox PJ, Bruss M, Hamon M, Bonisch H, Giros B. Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity. J Biol Chem. 2001;276:8254-8260.
19. Paczkowski FA, Bonisch H, Bryan-Lluka LJ. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter. Pharmacogenetics. 2002;12:165-173.
20. Roman DL, Walline CC, Rodriguez GJ, Barker EL. Interactions of antidepressants with the serotonin transporter: a contemporary molecular analysis. Eur J Pharmacol. 2003;479:53-63.
21. Barker EL, Blakely RD. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol. 1996;50:957-965.
22. Schloss P, Williams DC. The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol. 1998;12:115-121.
23. Vetulani J, Nalepa I. Antidepressants: past, present and future. Eur J Pharmacol. 2000;405:351-363.
24. Qian Y, Galli A. Ramamoorthy S, Risso S, DeFelice LJ, Blakely RD. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci. 1997;17:45-57.
25. Ramamoorthy S, Giovanetti E, Qian Y, Blakely RD. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem. 1998;273:2458-2466.
26. Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science. 1999;285:763-766.
27. Donati RJ, Rasenick MM. G protein signaling and the molecular basis of antidepressant action. Life Sci. 2003;73:1-17.
28. Ramamoorthy S, Cool DR, Mahesh VB, et al. Regulation of the human serotonin transporter. Cholera toxin-induced stimulation of serotonin uptake in human placental choriocarcinoma cells is accompanied by increased scrotonin transporter mRNA levels and serotonin transporter-specific ligand binding. J Biol Chem. 1993;268:21626-21631.
29. Zhu CB, Hewlett WA, Feoktistov I, Biaggioni I, Blakely RD. Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation. Mol Pharmacol. 2004;65:1462-1474.
30. Miller KJ, Hoffman BJ. Adenosine A3 receptors regulate serotonin transport via nitric oxide and eGMP. J Biol Chem. 1994;269:27351-27356.
31. Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci. 2005,25:29-41.
32. Haase J, Killian AM, Magnani F, Williams C. Regulation of the serotonin transporter by interacting proteins. Biochem Soc Trans. 2001;29:722-728.
33. Quick MW. Role of syntaxin 1A on serotonin transporter expression in developing thalamocortical neurons. Int J Dev Neurosci. 2001;20:219-224.
34. Quick MW. Regulating the conducting states of a mammalian serotonin transporter. Neuron. 2003;40:537-549.
35. Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, Blakely RD. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci. 2000;120:7571-7578.
36. Rausch JL, Gillespie CF, Fei Y. Antidepressant effects on kinase gene expression patterns in rat brain. Neurosci Lett. 2002;334:91-94.
37. Gelenberg AJ, Chesen CL. How fast are antidepressants? J Clin Psychiatry. 2000;161:712-721.
38. Potter WZ, Hollister LE. Antidepressant agents. In: Katzung BG, ed. Basic & Clinical Pharmacology New York: Lange Medical Books /McGraw-Hill; 2004:482-496.
39. Horschitz S, Hummerich R, Schloss P. Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor. Neuroreport. 2001;12:2181-2184.
40. Benmansour S, Cecchi M, Morilak DA. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci. 1999;19:10494-10501.
41. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci. 2002;22:6766-6772.
42. Gould GG, Pardon MC, Morilak DA, Frazer A. Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems. Neuropsychopharmacology. 2003;28:1633-1641.
43. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28:413-420.
44. Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol. 2001;16:229-236.
45. Alvarez JC, Gluck N, Arnulf I, et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther. 1999;66:617-624.
46. Hébert C, Habimana A, Élie R, Reader TA. Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study. Neurochem Int. 2001;38:63-74.
47. Yau JL, Kelly PA, Olsson T, Noble J, Seckl JR. Chronic amitriptyline administration increases serotonin transporter binding sites in the hippocampus of aged rats. Neurosci Lett. 1999;261:183-185.
48. Lima L, Urbina M. Scrotonin transporter modulation in blood lymphocytes from patients with major depression. Cell Mol Neurobiol. 2002;22:797-804.
49. Schloss P, Henn FA. New insights into the mechanisms of antidepressant therapy. Pharmacol Ther. 2004;102:47-60.
50. Piñeyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev. 1999;51:533-591.
51. Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29:252-265.
52. Hensler JG. Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology. 2002;26:565-573.
53. Ase AR, Reader TA, Hen R, Riad M, Descarries L. Regional changes in density of serotonin transporter in the brain of 5-HT1A and 5-HT1B knockout mice, and of serotonin innervation in the 5-HT1B knockout. J Neurochem. 2001;78:619-630.
54. Daws LC, Gerhardt GA, Frazer A. 5-HT1B antagonists modulate clearance of extracellular serotonin in rat hippocampus. Neurosci Lett. 1999;266:165-168.
55. Daws LC, Gould GG, Teicher SD, Gerhardt GA, Frazer A. 5-HT(1B) receptor-mediated regulation of serotonin clearance in rat hippocampus in vivo. J Neurochem. 2000;75:2113-2122.
56. Malagié I, David DJ, Jolliet P, Hen R, Bourin M, Gardier AM. Improved efficacy of fluoxetine in increasing hippocampal 5-hydroxytryptamine outflow in 5-HT1B receptor knock-out mice. Eur J Pharmacol. 2002;443:99-104.
57. Neumaier JF, Root DC, Hamblin MW. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology. 1996;15:515-522.
58. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51:248-251.
59. Shalom G, Gur E, Van de Kar LD, Newman ME. Repeated administration of the 5-HT(1B) receptor antagonist SB-224289 blocks the desensitisation of 5-HT(1B) autoreceptors induced by fluoxetine in rat frontal cortex. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:84-90.
60. Ansah TA, Ramamoorthy S, Montanez S, Daws LC, Blakely RD. Calcium-dependent inhibition of synaptosomal serotonin transport by the alpha 2-adrenoceptor agonist 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine (UK14304). J Pharmacol Exp Ther. 2003;305:956-965.
61. Ramamoorthy S, Bauman AL, Moore KR, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA. 1993;90:2542-2546.
62. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621-2624.
63. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531.
64. Rausch JL, Johnson ME, Fei YJ, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry. 2002;51:723-732.
65. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry. 2002;7:1115-1119.
66. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23:587-590.
67. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004;174:525-529.
68. Ozaki N, Goldman D, Kaye WH, et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry. 2003;8:933-936.
69. Kilic F, Murphy DL, Rudnick G. A human serotonin transporter mutation causes constitutive activation of transport activity. Mol Pharmacol. 2003;64:440-446.
70. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35:298-306.
71. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998;62:583-606.
72. Pfennig A, Kunzel BE, Kern N, et al. Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol Psychiatry. 2005;57:336-342.
73. Capuron L, Ravaud A, Nevcu PJ, Miller AH, Macs M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7:468-473.
74. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906-914.
75. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:201-217.
76. Bschor T, Baethge C, Adli M, Lewitzka U, Eichmann U, Bauer M. Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression. J Psychiatry Neurosci. 2003;28:210-216.
77. Sauvage MF, Marquet P, Rousseau A, Raby C, Buxeraud, Lachatre G. Relationship between psychotropic drugs and thyroid function: a review. Toxicol Appl Pharmacol. 1998;149:127-135.
78. Shelton RC, Winn S, Ekhatore N, Loosen PT. The effects of antidepressants on the thyroid axis in depression. Biol Psychiatry. 1993;33:120-126.
79. Duval F, Mokrani MC, Crocq MA, et al. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Arch Gen Psychiatry. 1996;53:833-840.
80. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365-2372.
81. Wallace TL, Stellitano KE, Neve RL, Duman RS. Effects of cyclic adenosine monophosphate response element binding protein overexpression in the basolateral amygdala on behavioral models of depression and anxiety. Biol Psychiatry. 2004;56:151-160.
82. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70-75.
83. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5:11-25.
84. Coppell AL, Pei Q, Zetterstrom TS. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology. 2003;44:903-910.
85. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci. 2002;22:3262-3268.
86. Pullar IA, Boot JR, Broadmore RJ. The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. Eur J Pharmacol. 2004;493:85-93.
87. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Nicol Ferrier I. Improvements in neurocognitive function and mood following adjunctive treatment with mitepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29:1538-1545.
88. Bao AM, Hestiantoro A, Van Someren EJ, Swaab DF, Zhou JN. Colocalization of corticotropin-releasing hormone and oestrogen receptor-{alpha} in the paraventricular nucleus of the hypothalamus in mood disorders. Brain. 2005.
89. Dableh LJ, Yashpal K, Rochford J, Henry JL. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol. 2005;507:99-105.